ERBB2 and neoplasm: These data are consistent with other data from KATHERINE showing that biomarkers assessed in the surgical sample affected outcomes in the trastuzumab arm, but not in the T-DM1 arm12, however they are limited in that paired sample data were not available from all patients because of insufficient tumor material and/or invalid or unknown HER2 status results.